摘要
目的对直肠癌患者采取术前新辅助化疗联合全直肠系膜切除术治疗,分析其治疗效果。方法实验组采取术前新辅助FOLFOX4方案化疗联合全直肠系膜切除术,对照组仅行全直肠系膜切除术。比较2组患者手术的基本情况;实验组患者治疗前后TNM分期的变化;实验组患者治疗前后癌胚抗原(CEA)及糖链抗原(CA19-9、CA242、CA724)等肿瘤标志物水平的变化;2组患者的治疗效果及并发症的发生。结果实验组与对照组在手术时间、术中出血量、住院时间、肿瘤直径、总体费用等方面差异无统计学意义(P>0.05)。与治疗前比较,实验组治疗后分期有所降低,肿瘤标志物CEA、CA19-9、CA242、CA724均下降(P<0.05)。实验组患者根治率、保肛率、生存率均较对照组明显升高,复发率低于对照组(P<0.05);实验组患者并发症发生率低于对照组(P<0.05)。结论对直肠癌患者采取术前新辅助化疗联合手术治疗,能够降低临床分期,降低肿瘤标志物水平,提高根治率、保肛率、生存率,降低复发率及并发症发生率。
Objective To study the efficacy of neoadjuvant chemotherapy combined with TME surgery in the treatment of colorectal cancer.Methods The experimental group received FOLFOX 4 neoadjuvant chemotherapy combined with TME surgery , the control group received TME surgery ,the basic operation situation of the 2 groups were compared;change of TNM staging and CEA、CA19-9、CA242、CA724 before and after surgery of the experimental group were compared;effects and complications of the 2 groups were compared.Results The operative time,blood loss,hospital stay,tumor diameter,the overall costs between the 2 groups showed no significant difference （ P〉0.05）;Compared with before treatment ,the experimental group decreased after treat-ment staging,tumor markers CEA,CA19-9,CA242,CA724 decreased（P〈0.05）;Cure rate,sphincter preservation rate,and sur-vival rate of the experimental group was significantly higher than the control group ,the recurrence rate was lower than the control group（ P〈0.05）;The incidence of complications in the experimental group was significantly lower than the control group （ P〈0.05）.Conclusion Neoadjuvant chemotherapy combined with surgery for colorectal cancer can reduce the clinical stage ,lower levels of tumor markers ,increase cure rate ,sphincter preservation rate ,survival rate ,reduce the relapse rate and incidence of com-plications.
出处
《实用癌症杂志》
2017年第1期71-73,共3页
The Practical Journal of Cancer
